Cellerant Therapeutics, Inc. — Department of Health and Human Services SBIR Phase II: NCI
Cellerant Therapeutics, Inc. — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $1,496,276
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- Topic
- NCI
- NAICS
- —
- Place of performance
- CA
- Period
- —
Description
The effectiveness of current AML treatments is abysmal yielding only an overall year survival rate of and it has been hypothesized that the treatment may be more durable if leukemic stem cells LSC are eliminated IL RAP is a compelling target because it is expressed on LSC in majority of AML patients but not on healthy hematopoietic stem cells Also suppressing IL RAP expression in AML cells can greatly inhibit tumor cell growth survival From SBIR Phase I contract the contractor developed various antibodies against IL RAP having functional blocking properties a higher affinity for membrane bound IL RAP relative to the secreted form and tumor cell inhibition activities